The evolving biotechnology industry continues to develop new and exciting therapeutic approaches to long standing clinical problems. Biotechnology was initially founded to apply recombinant genetic engineering to produce new pharmacologic agents. This fundamental approach consisted of isolating a single protein made by cells, isolating the gene for this protein, and using recombinant molecular biologic techniques to introduce this gene into expression systems to produce large quantities of the gene product. Human growth hormone, human insulin and human erythropoietin are examples of the implementation and success of this strategy. Such successes, however, have been less common than anticipated because the use of an isolated single protein for identified useful pharmacological purposes has been extremely difficult to achieve for several reasons. Physiological responses are usually due to a complex interaction of a network of proteins, so that a single protein (or lack thereof) is rarely responsible for a targeted physiologic function or a targeted disease process. Even if a single protein, such as a hormone, is criticaly important in a disease process, protein degradation in the gastrointestinal tract precludes oral administration. Intravenous or subcutaneous injections are more advantageous but less easy to administer. Even with appropriate injectable formulations, targeted delivery to the site of useful efficacy may expose other tissues to the protein with unwanted or toxic side effects, so that optimal dosing strategies may require careful and expensive ongoing evaluation of the compound's effects on the physiologic or pathophysiologic process.
In this regard, cell therapy and tissue engineering may be the next successful strategies in biotechnology to overcome these prior difficulties as well as to replace the lost physiologic function of a diseased solid organ. Cell therapy is based on the idea that various cells can be cultured in vitro to perform specific differentiated biologic tasks and immunoisolated with encapsulation synthetic membranes. Tissue engineering expands this approach to use cells to replace a complex set of physiologic functions of a diseased nonfunctional organ (1) . Substantial progress has been made in the development of a bioartificial pancreas to deliver regulated insulin in the diabetic state and a bioartificial liver to bridge a patient with end-stage liver disease to transplantation (2, 3). Successful development of a functional and implantable tissue-engineered glomerular filter and tubule reabsorber from a combination of cells, biomaterials and synthetic polymers to replace renal excretory and regulatory functions may produce an implantable device to replace lost renal function and present a cure to end-stage renal disease (ESRD).
Tissue-engineering approach to renal function replacement
The kidney was the first organ whose function was substituted by an artificial device. The kidney was also the first organ to be successfully transplanted. The ability to replace renal function with these revolutionary technologies in the past was due to the fact that renal excretory function is based upon natural physical forces which govern solute and fluid movement from the body compartment to the external environment. The need for coordinated mechanical or electrical activities for renal substitution is not required. Accordingly, the kidney may well be the first organ to be available as a tissue-engineered implantable device that is a fully functional replacement part for the human body.
In designing an implantable bioartificial kidney for renal replacement function, essential functions of kidney tissue must be utilized to direct the design of the tissue-engineering project. The critical elements of renal function must be replaced, including the excretory, reabsorptive, metabolic, and endocrinologic functions. The functioning excretory unit of the kidney is composed of the filtering unit, the glomerulus, and the regulatory or reabsorptive unit, the tubule. Therefore, a bioartificial kidney requires two main units, the glomerulus and the tubule, to replace renal excretory function.
Development of an implantable device which mimics glomerular filtration will be dependent upon convective transport (4, 5) . This physiologic function has been achieved clinically with the use of polymeric hollow fibers ex vivo (6) (7) (8) (9) . Major limitations to the currently available technology for long-term replacement of filtration function include bleeding associated with required anticoagulation, diminution of filtration rate due to protein deposition in the membrane over time and thrombotic occlusion, along with the requirement for large amounts of fluid replacement to replace the ultrafiltrate formed from the filtering unit. The use of endothelial-cell-seeded conduits along filtration surfaces may provide improved long-term hemocompatibility and hemofiltration in vivo (10) (11) (12) . In this regard, the initial step to develop a tissue-engineered hemofilter with adequate ultrafiltration rates through an endothelial-lined synthetic hemofiltration membrane has recently been achieved (13) . Because of the continuous contact of the recipients blood with the implanted endothelial cells of the bioartificial hemofilter, only autologous endothelial cells can be used in the construction of this device. The rapid isolation and growth of endothelial cells from various tissues provides a broad spectrum of potential sources for autologous endothelial cells (14) .
An important additional potential rate-limiting step in endothelial-cell-lined hollow fibers of small caliber is thrombotic occlusion, which limits the functional patent of this filtration unit. In this regard, gene transfer into seeded endothelial cells for constitutive expression of anticoagulant factors can be envisioned to minimize clot formation in these small-caliber hollow fibers. Since gene transfer for in vivo protein production has been clearly achieved with endothelial cells (15, 16) , gene transfer into endothelial cells for the production of an anticoagulant protein is clearly conceivable.
The bioartificial renal tubule is also clearly feasible when conceived as a combination of living cells supported on polymeric substrata (17) . A bioartificial tubule uses epithelial progenitor cells (17, 18) cultured on water and solute-permeable membranes seeded with various biomatrix materials so that expression of differentiated vectorial transport and metabolic and 216 endocrine function is attained. With appropriate membranes and biomatrices, immunoprotection of cultured progenitor cells can be achieved concurrent with long-term functional performance as long as conditions support tubule cell viability (19, 20) . The technical feasibility of an implantable epithelial cell system derived from cells grown as confluent monolayers along the luminal surface of polymeric hollow fibers has been achieved (29).
The development of a bioartificial filtration device and a bioartificial tubule processing unit would lead to the possibility of an implantable bioartificial kidney, consisting of the filtration device followed in series by the tubule unit. The filtrate formed by this device will flow directly into the tubule unit. The tubule unit should maintain viability, because metabolic substrates and low-molecular-weight growth factors are delivered to the tubule cells from the ultrafiltration unit. Furthermore, immunoprotection of the cells grown within the hollow fiber is achievable due to the impenetrance of immunologically competent cells through the hollow fiber. Rejection of transplanted cells will, therefore, not occur. This arrangement thereby allows the filtrate to enter the internal compartments of the hollow fiber network, which are lined with confluent monolayers of renal tubule cells for regulated transport function.
This device could be used either extracorporeally or implanted within a patient. In this regard, the specific implant site for a bioartificial kidney will depend upon the final configuration of both the bioartificial filtration and tubule device. As presently conceived, the endothelial-lined bioartificial filtration holiow fibers can be placed into an arteriovenous circuit using the common iliac artery and vein, similar to the surgical connection for a renal transplant. The filtrate is connected in series to a bioartificial proximal tubule with the reabsorbate transported back into the systemic circulation. The processed filtrate exiting the tubule unit is then connected via tubing to the proximate ureter for drainage and urine excretion via the recipient's own urinary collecting system.
Finally, a cell therapy approach for the regulated and homeostatic production of erythropoietin to maintain normal circulating red blood cell mass is also being developed. Cell therapy is based upon the ability to immunoisolate allogeneic or xenogeneic cells with semipermeable membranes and to implant these encapsulated cells into an individual for targeted or regulated delivery of a pre-selected moleculer. In this regard, cells have been identified with oxygen (02)-regulated erythropoietin production, and successful encapsulation of cells at a high cell density has been achieved. An intravascular cell delivery device to maintain cell viability and 02-regulated erythropoietin production in vivo is being developed and tested in vivo (22) .
In conclusion, cell therapy and tissue engineering, may well likely dominate medical therapeutics in the next century. Growing a functional glomerular filter and tubule reabsorber from a combination of cells, biomaterials and synthetic polymers to replace renal excretory and regulatory functions is a specific exam-
